Video Experimental Relacionado
Updated: Jun 12, 2025
06:12
Author Spotlight: THP-1 Macrophage Response to LPS/ATP — Unveiling the Pyroptosis, Apoptosis, and Necroptosis Spectrum
Published on: May 3, 2024
1.7K
KRAS toma el camino de la destrucción
Adrienne D Cox1,2,3, Channing J Der2,3
1Department of Radiation Oncology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Science (New York, N.Y.)
|September 19, 2024
Resumen
Un nuevo fármaco de molécula pequeña degrada eficazmente múltiples variantes de KRAS, ofreciendo una estrategia terapéutica prometedora para varios tipos de cáncer. Este avance se dirige a los impulsores clave del crecimiento del tumor.
Área de la Ciencia:
- En el campo de la oncología
- Biología molecular
- Descubrimiento de drogas
Sus antecedentes:
- Las mutaciones KRAS son frecuentes en muchos cánceres humanos, incluidos los cánceres de páncreas, pulmón y colorrectal.
- Las terapias existentes dirigidas a KRAS tienen una eficacia limitada debido al desafío de dirigirse a esta proteína "indrugable".
- Las variantes específicas de KRAS impulsan el inicio y la progresión del tumor, lo que las convierte en objetivos terapéuticos críticos.
Objetivo del estudio:
- Identificar y caracterizar una nueva molécula pequeña capaz de degradar múltiples variantes oncogénicas de KRAS.
- Evaluar el potencial terapéutico de esta pequeña molécula en modelos preclínicos de cáncer.
- Para aclarar el mecanismo de acción de la degradación de la variante KRAS.
Principales métodos:
- Cribado de alto rendimiento para identificar inhibidores de moléculas pequeñas de variantes de KRAS.
- Pruebas bioquímicas para confirmar el compromiso y la degradación del objetivo.
- Ensayos basados en células para evaluar la eficacia de la pequeña molécula en líneas celulares cancerosas.
- Estudios in vivo en modelos animales para evaluar los efectos terapéuticos.
Principales resultados:
- Se identificó una sola molécula pequeña que degrada potentemente múltiples variantes KRAS clínicamente relevantes (por ejemplo, G12D, G12V, G12C).
- La molécula demostró una inhibición significativa del crecimiento tumoral en modelos preclínicos que albergaban mutaciones KRAS.
- El mecanismo de acción confirmó la degradación directa de las proteínas KRAS, lo que lleva a la inhibición de la vía descendente.
Conclusiones:
- Una nueva molécula pequeña degrada efectivamente numerosas variantes oncogénicas de KRAS.
- Este hallazgo presenta una nueva vía terapéutica potencial para una amplia gama de cánceres impulsados por KRAS.
- Se requiere una investigación clínica adicional para explorar la eficacia y seguridad de este fármaco candidato.
Videos de Conceptos Relacionados
01:17The Extrinsic Apoptotic Pathway
6.3K
The extrinsic apoptotic pathway is initiated when extracellular death-inducing signals, such as specific cytokines, activate the death receptors expressed on the cell surface. The immune cells involved in this pathway are natural killer cells (NK cells) and cytotoxic T-lymphocytes. NK cells are critical in innate immune response, while cytotoxic T-lymphocytes are associated with adaptive immune response. These cells recognize specific receptors expressed on the altered cells and activate...
6.3K
01:31The Intrinsic Apoptotic Pathway
6.4K
Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
6.4K
01:07MAPK Signaling Cascades
5.3K
Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
5.3K
01:16Necrosis
4.4K
Necrosis is considered as an “accidental” or unexpected form of cell death that ends in cell lysis. The first noticeable mention of “necrosis” was in 1859 when Rudolf Virchow used this term to describe advanced tissue breakdown in his compilation titled “Cell Pathology”.
Morphological Manifestations of Necrosis
Necrotic cells show different types of morphological appearance depending on the type of tissue and infection. In coagulative necrosis, cells become...
Morphological Manifestations of Necrosis
Necrotic cells show different types of morphological appearance depending on the type of tissue and infection. In coagulative necrosis, cells become...
4.4K
01:30Apoptosis
11.2K
Apoptosis is a combination of two Greek words, 'apo' and 'ptosis,' meaning separation and falling off, respectively. Hippocrates used this word to describe gangrene, which was caused due to bandaging of fractured bones. Apoptosis was distinguished from necrosis in 1970 when John Kerr reported observations of morphological changes occurring during apoptosis. During one experiment, he observed that the disruption of blood supply to the liver tissue resulted in a size...
11.2K
01:24Caspases
12.4K
Caspase, a family of cysteine proteases, serve as effectors in apoptosis. The ced3 gene in C.elegans was first identified to be involved in apoptosis. This gene encodes the ced-3 caspase that is similar to the interleukin-1-beta converting enzyme or ICE in mammals. In addition to apoptosis, caspases also function in the inflammatory response. Inflammatory caspases are essential in activating pro-inflammatory cytokines that recruit immune cells and block the replication of pathogens inside...
12.4K